Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021

Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan & listed on the London Stock Exchange market in July 2021 raising £25m.

A clinical-stage infectious diseases pharmaceutical company, with an exciting pipeline of assets, unrivalled expertise and a business model that sets us apart.


Their ambition is to become a “one-stop-shop” for pharma to find Phase II ready products for development and commercialisation.

Spun out of Open Orphan plc in 2021, we have access to over 20 years of knowledge, expertise, and clinical data from human viral challenge studies.

Focused on using advanced scientific practices in the research and development of vaccines and treatments for infectious diseases.

We have a novel capital-light clinical model which means we can develop products quickly and more cost-effectively than other biotechs with plans to rapidly partner with Pharma companies for commercialisation.



Poolbeg Pharma is a publicly-traded company on the London AIM stock exchange under the ticker POLB

Poolbeg Pharma is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables us to develop multiple products faster and more cost-effectively than the traditional biotech model. Poolbeg aspires to become a “one-stop-shop” for big pharma to find Phase II ready products for commercialisation.

With access to knowledge, experience and clinical data from over 20 years of human challenge trials, we use our insights to reposition clinical-stage products, reducing spending and risk.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned